Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHANCE trial of atezolizumab in pretreated advanced NSCLC with rare histologic subtypes
2018-002607-34Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoints: Disease control rate, Tumor response categories and 1 more. Started Jan 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-002607-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002607-34.